Atherosclerotic Cardiovascular Disease
Conditions
Interventions
Group of Inclisiran:NA
Traditional treatment group:NA
Sponsors
Shengjing Hospital of China Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients with baseline age >= 18 years, regardless of gender, diagnosed with high risk of ASCVD (refer to 2023 Chinese Blood Lipid Guidelines ); 2. Received moderate doses of statins when participating in the study; 3. Those who received Inclisiran were included in the combination group of Inclisiran, and those who received other lipid-lowering drugs were included in the traditional treatment group.
Exclusion criteria
Exclusion criteria: The combination group of Inxilam needs to exclude those who have received Inclisiran treatment within 2 years before participating in the study or PCSK9 monoclonal antibody within 3 months before participating in the study; Participating in other cardiovascular trials at time of inclusion ; Have severe liver disease (Child-Pugh class C); Severe anemia (hemoglobin <7 g / dl); Autoimmune diseases (systemic lupus erythematosus, etc.); Pregnancy status; Critically ill patients with life expectancy < 15 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in LDL-C levels;Rate of achieving LDL-C targets; | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in LDL-C variability;Changes in other lipid parameters;Proportion of patients with lipid-lowering medication PDC >= 80 %;Mean days of coverage; | — |
Countries
China
Contacts
Public ContactZhang Daqing
Shengjing Hospital of China Medical University
Outcome results
None listed